Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa.
SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Observatory, 7925, South Africa.
Eur J Med Chem. 2021 Mar 5;213:113207. doi: 10.1016/j.ejmech.2021.113207. Epub 2021 Jan 24.
Nitro based DprE1 inhibitors exemplified by benzothiazinones have been reported to elicit potent anti-tubercular activity. Poor PK properties associated with benzothiazinones have inspired the discovery of alternative nitro based DprE1 inhibitors. Quinolone based antibiotics on the other hand have good PK properties. The potent anti-tubercular activity of nitro compounds and the good PK properties of the quinolones have elicited an interest in us to construct a new class of nitro containing compounds around the quinolone scaffold with the aim of identifying novel DprE1 inhibitors with potent anti-tubercular activity. Thus, we report herein the anti-tubercular activity of novel 6-nitroquinolone-3-carboxamide derivatives achieved using less than five cheap synthetic transformations. Among the 23 target compounds evaluated for anti-tubercular activity, 12 were active against Mtb─ exhibiting activity in the range of <0.244-31.865 μM. Compound 25 having a molecular weight of 399 Da and ClogP value of 2.7 is the most active (MIC: <0.244 μM) in this series. The SAR analyses suggest that anti-tubercular activity was influenced by substituents at position N-1 (R) and C-3 (R) of the quinolone ring. The activity data suggest that the nature of R has a stronger influence on the SAR compared to R; with a fluorobenzyl and chlorobenzyl moiety at R being the most favoured when R is an aliphatic amine. Docking study confirms that compound 25 binds to the same hydrophobic pocket as does TCA1, and other nitro based DprE1 inhibitors, with its nitro group in close proximity with Cys387 residue.
基于硝基的 DprE1 抑制剂,如苯并噻嗪酮,已被报道具有很强的抗结核活性。苯并噻嗪酮较差的 PK 特性激发了对替代硝基 DprE1 抑制剂的发现。另一方面,喹诺酮类抗生素具有良好的 PK 特性。硝基化合物的强抗结核活性和喹诺酮类药物的良好 PK 特性引起了我们的兴趣,我们在喹诺酮骨架周围构建了一类新的含硝基化合物,旨在确定具有强抗结核活性的新型 DprE1 抑制剂。因此,我们在此报告了使用不到五次廉价的合成转化来实现新型 6-硝基喹诺酮-3-甲酰胺衍生物的抗结核活性。在所评估的 23 种抗结核活性的目标化合物中,有 12 种对 Mtb 有效,活性范围在 <0.244-31.865 μM 之间。具有 399 Da 分子量和 2.7 的 ClogP 值的化合物 25 是该系列中最活跃的(MIC:<0.244 μM)。SAR 分析表明,取代基在喹诺酮环的 N-1(R)和 C-3(R)位置对抗结核活性有影响。活性数据表明,与 R 相比,R 的取代基对 SAR 的影响更强;当 R 为脂肪族胺时,R 上带有氟苄基和氯苄基部分是最有利的。对接研究证实,化合物 25 与 TCA1 和其他基于硝基的 DprE1 抑制剂一样,结合在相同的疏水性口袋中,其硝基基团与 Cys387 残基非常接近。